158 related articles for article (PubMed ID: 33499323)
1. C1q-HA Matrix Regulates the Local Synthesis of Hyaluronan in Malignant Pleural Mesothelioma by Modulating HAS3 Expression.
Vidergar R; Balduit A; Zacchi P; Agostinis C; Mangogna A; Belmonte B; Grandolfo M; Salton F; Biolo M; Zanconati F; Confalonieri M; Bulla R
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33499323
[TBL] [Abstract][Full Text] [Related]
2. Complement protein C1q stimulates hyaluronic acid degradation
Balduit A; Vidergar R; Zacchi P; Mangogna A; Agostinis C; Grandolfo M; Bottin C; Salton F; Confalonieri P; Rocca A; Zanconati F; Confalonieri M; Kishore U; Ghebrehiwet B; Bulla R
Front Immunol; 2023; 14():1151194. PubMed ID: 37334363
[TBL] [Abstract][Full Text] [Related]
3. Complement Protein C1q Binds to Hyaluronic Acid in the Malignant Pleural Mesothelioma Microenvironment and Promotes Tumor Growth.
Agostinis C; Vidergar R; Belmonte B; Mangogna A; Amadio L; Geri P; Borelli V; Zanconati F; Tedesco F; Confalonieri M; Tripodo C; Kishore U; Bulla R
Front Immunol; 2017; 8():1559. PubMed ID: 29209316
[TBL] [Abstract][Full Text] [Related]
4. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
5. Rab10-mediated endocytosis of the hyaluronan synthase HAS3 regulates hyaluronan synthesis and cell adhesion to collagen.
Deen AJ; Rilla K; Oikari S; Kärnä R; Bart G; Häyrinen J; Bathina AR; Ropponen A; Makkonen K; Tammi RH; Tammi MI
J Biol Chem; 2014 Mar; 289(12):8375-89. PubMed ID: 24509846
[TBL] [Abstract][Full Text] [Related]
6. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Cho H; Matsumoto S; Fujita Y; Kuroda A; Menju T; Sonobe M; Kondo N; Torii I; Nakano T; Lara PN; Gandara DR; Date H; Hasegawa S
J Thorac Oncol; 2017 Mar; 12(3):477-490. PubMed ID: 27867002
[TBL] [Abstract][Full Text] [Related]
7. Pemetrexed-conjugated hyaluronan for the treatment of malignant pleural mesothelioma.
Amano Y; Ohta S; Sakura KL; Ito T
Eur J Pharm Sci; 2019 Oct; 138():105008. PubMed ID: 31302213
[TBL] [Abstract][Full Text] [Related]
8. Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.
Shigeeda W; Shibazaki M; Yasuhira S; Masuda T; Tanita T; Kaneko Y; Sato T; Sekido Y; Maesawa C
Oncotarget; 2017 Nov; 8(55):93729-93740. PubMed ID: 29212185
[TBL] [Abstract][Full Text] [Related]
9. Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma.
Sasai M; Nakamura H; Sougawa N; Sakurai Y; Suzuki M; Lee CM
Anticancer Res; 2016 Mar; 36(3):907-11. PubMed ID: 26976977
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Enhancement of Cellular Uptake With CD44-Expressing Malignant Pleural Mesothelioma by Combining Cationic Liposome and Hyaluronic Acid-Lipid Conjugate.
Sakurai Y; Kato A; Hida Y; Hamada J; Maishi N; Hida K; Harashima H
J Pharm Sci; 2019 Oct; 108(10):3218-3224. PubMed ID: 31229434
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid in the pleural fluid of patients with malignant pleural mesothelioma.
Fujimoto N; Gemba K; Asano M; Fuchimoto Y; Wada S; Ono K; Ozaki S; Kishimoto T
Respir Investig; 2013 Jun; 51(2):92-7. PubMed ID: 23790737
[TBL] [Abstract][Full Text] [Related]
12. Super Enhancer Driven Hyaluronan Synthase 3 Promotes Malignant Progression of Nasopharyngeal Carcinoma.
Chen Q; Peng Q; Cai J; Liu Y; Lu X; Xiong W; Zeng Z; Li G; Li X; Li X; Xiang B; Yi M; Chen P
J Cancer; 2023; 14(10):1751-1762. PubMed ID: 37476195
[TBL] [Abstract][Full Text] [Related]
13. HAS3-induced extracellular vesicles from melanoma cells stimulate IHH mediated c-Myc upregulation via the hedgehog signaling pathway in target cells.
Arasu UT; Deen AJ; Pasonen-Seppänen S; Heikkinen S; Lalowski M; Kärnä R; Härkönen K; Mäkinen P; Lázaro-Ibáñez E; Siljander PR; Oikari S; Levonen AL; Rilla K
Cell Mol Life Sci; 2020 Oct; 77(20):4093-4115. PubMed ID: 31820036
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronan synthase 3 mediated oncogenic action through forming inter-regulation loop with tumor necrosis factor alpha in oral cancer.
Kuo YZ; Fang WY; Huang CC; Tsai ST; Wang YC; Yang CL; Wu LW
Oncotarget; 2017 Feb; 8(9):15563-15583. PubMed ID: 28107185
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer.
Adamia S; Maxwell CA; Pilarski LM
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):3-14. PubMed ID: 15720220
[TBL] [Abstract][Full Text] [Related]
16. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages.
Chéné AL; d'Almeida S; Blondy T; Tabiasco J; Deshayes S; Fonteneau JF; Cellerin L; Delneste Y; Grégoire M; Blanquart C
J Thorac Oncol; 2016 Oct; 11(10):1765-73. PubMed ID: 27418105
[TBL] [Abstract][Full Text] [Related]
17. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
18. Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis.
Bharadwaj AG; Rector K; Simpson MA
J Biol Chem; 2007 Jul; 282(28):20561-72. PubMed ID: 17502371
[TBL] [Abstract][Full Text] [Related]
19. Extensive CD44-dependent hyaluronan coats on human bone marrow-derived mesenchymal stem cells produced by hyaluronan synthases HAS1, HAS2 and HAS3.
Qu C; Rilla K; Tammi R; Tammi M; Kröger H; Lammi MJ
Int J Biochem Cell Biol; 2014 Mar; 48():45-54. PubMed ID: 24406795
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of extracellular matrix constituents and cell adhesion molecules between malignant pleural mesothelioma and mesothelial hyperplasia.
Alì G; Borrelli N; Riccardo G; Proietti A; Pelliccioni S; Niccoli C; Boldrini L; Lucchi M; Mussi A; Fontanini G
J Thorac Oncol; 2013 Nov; 8(11):1389-95. PubMed ID: 24084442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
